scispace - formally typeset
Search or ask a question
Author

Yeu-Ching Shi

Bio: Yeu-Ching Shi is an academic researcher from Taipei Medical University. The author has contributed to research in topics: Lipogenesis & mitochondrial fusion. The author has an hindex of 1, co-authored 2 publications receiving 4 citations.

Papers
More filters
Journal ArticleDOI
TL;DR: In this paper, the authors showed that Paris polyphylla inhibited the growth of colorectal cancer (CRC) cells, and they also found that extracellular vesicles (EVs) released from Fusobacterium nucleatum could promote mitochondrial fusion and cell invasion in CRC cells.
Abstract: Colorectal cancer (CRC) is one of the most common cancers worldwide. Gut microbiota are highly associated with CRC, and Fusobacterium nucleatum was found to be enriched in CRC lesions and correlated with CRC carcinogenesis and metastases. Paris polyphylla is a well-known herbal medicine that showed anticancer activity. The present study demonstrates that P. polyphylla inhibited the growth of CRC cells. In addition, treating with active compounds pennogenin 3-O-beta-chacotrioside and polyphyllin VI isolated from P. polyphylla inhibited the growth of F. nucleatum. We also found that extracellular vesicles (EVs) released from F. nucleatum could promote mitochondrial fusion and cell invasion in CRC cells, whereas active components from P. polyphylla could dampen such an impact. The data suggest that P. polyphylla and its active ingredients could be further explored as potential candidates for developing complementary chemotherapy for the treatment of CRC.

13 citations

Journal ArticleDOI
TL;DR: The data showed that cordycepin decreased lipid accumulation via activating AMPK and regulating mitochondrial function in oleic acid‐induced mouse FL83B hepatocytes while the anti‐fatty liver effect of Cordycepins on regulating lipogenesis and fatty beta‐oxidation was abolished by AMPK inhibitor compound C treatment.
Abstract: Compound cordycepin (3′‐deoxyadenosine) has been used in cancer treatment, diabetes prevention, and anti‐virus, as well as hyperlipidemia downregulation in vivo. However, the association between lipid metabolism and mitochondrial activity in cordycepin‐treated hepatocytes is remain unclear. In this study, whether cordycepin affects lipogenesis and fatty beta‐oxidation through regulating mitochondrial activity and AMP‐activated protein kinase (AMPK) in hepatocytes were investigated. The data showed that cordycepin decreased lipid accumulation via activating AMPK and regulating mitochondrial function in oleic acid (OA)‐induced mouse FL83B hepatocytes while the anti‐fatty liver effect of cordycepin on regulating lipogenesis and fatty beta‐oxidation was abolished by AMPK inhibitor compound C treatment. These results suggested that cordycepin attenuated lipid accumulation through promoting beta‐oxidation and may be developed as a functional food/natural medicine for fatty liver suppression. PRACTICAL APPLICATIONS: Traditional herb, Chinese medicine, and functional food treatments for hyperlipidemia are relatively cheap and locally available. The results of this study suggested that cordycepin (active compound of Cordyceps) may be developed as functional foods for fatty liver treatment via regulating fatty beta‐oxidation.

5 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: Several herbal formulas, herbs or herbal derivatives, such as Erchen Dection, Danshen, resveratrol, and berberine, which have been extensively studied for their promising potential in mediating lipid metabolism are particularly highlighted in this review.
Abstract: The dysregulation of hepatic lipid metabolism is one of the hallmarks in many liver diseases including alcoholic liver diseases (ALD) and non-alcoholic fatty liver diseases (NAFLD). Hepatic inflammation, lipoperoxidative stress as well as the imbalance between lipid availability and lipid disposal, are direct causes of liver steatosis. The application of herbal medicines with anti-oxidative stress and lipid-balancing properties has been extensively attempted as pharmaceutical intervention for liver disorders in experimental and clinical studies. Although the molecular mechanisms underlying their hepatoprotective effects warrant further exploration, increasing evidence demonstrated that many herbal medicines are involved in regulating lipid accumulation processes including hepatic lipolytic and lipogenic pathways, such as mitochondrial and peroxisomal β-oxidation, the secretion of very low density lipoprotein (VLDL), the non-esterified fatty acid (NEFA) uptake, and some vital hepatic lipogenic enzymes. Therefore, in this review, the pathways or crucial mediators participated in the dysregulation of hepatic lipid metabolism are systematically summarized, followed by the current evidences and advances in the positive impacts of herbal medicines and natural products on the lipid metabolism pathways are detailed. Furthermore, several herbal formulas, herbs or herbal derivatives, such as Erchen Dection, Danshen, resveratrol, and berberine, which have been extensively studied for their promising potential in mediating lipid metabolism, are particularly highlighted in this review.

39 citations

Journal ArticleDOI
TL;DR: In this article, the effects of Cordycepin (CRD) on obesity-induced non-alcoholic fatty liver disease (NAFLD) were explored. And the results suggest that CRD can be a potential therapeutic agent in the prevention and treatment of NAFLD, which may be closely related to its effect on lipid metabolism and inflammatory responses.

16 citations

Journal ArticleDOI
TL;DR: Results suggest that cordycepin protects against post‐AB cardiac hypertrophy through activation of the AMPKα pathway, which subsequently attenuates oxidative stress.
Abstract: Increase of myocardial oxidative stress is closely related to the occurrence and development of cardiac hypertrophy. Cordycepin, also known as 3'-deoxyadenosine, is a natural bioactive substance extracted from Cordyceps militaris (which is widely cultivated for commercial use in functional foods and medicine). Since cordycepin suppresses oxidative stress both in vitro and in vivo, we hypothesized that cordycepin would inhibit cardiac hypertrophy by blocking oxidative stress-dependent related signalling. In our study, a mouse model of cardiac hypertrophy was induced by aortic banding (AB) surgery. Mice were intraperitoneally injected with cordycepin (20 mg/kg/d) or the same volume of vehicle 3 days after-surgery for 4 weeks. Our data demonstrated that cordycepin prevented cardiac hypertrophy induced by AB, as assessed by haemodynamic parameters analysis and echocardiographic, histological and molecular analyses. Oxidative stress was estimated by detecting superoxide generation, superoxide dismutase (SOD) activity and malondialdehyde levels, and by detecting the protein levels of gp91phox and SOD. Mechanistically, we found that cordycepin activated activated protein kinase α (AMPKα) signalling and attenuated oxidative stress both in vivo in cordycepin-treated mice and in vitro in cordycepin treated cardiomyocytes. Taken together, the results suggest that cordycepin protects against post-AB cardiac hypertrophy through activation of the AMPKα pathway, which subsequently attenuates oxidative stress.

14 citations

Journal ArticleDOI
TL;DR: The role of Gut microbiota in the pathogenesis of CRC, the potential of gut microbiota as biomarkers for CRC, and therapeutic approaches to CRC based on the regulation of gut bacteria are discussed.
Abstract: Colorectal cancer (CRC) ranks third in terms of global incidence and second in terms of death toll among malignant tumors. Gut microbiota are involved in the formation, development, and responses to different treatments of CRC. Under normal physiological conditions, intestinal microorganisms protect the intestinal mucosa, resist pathogen invasion, and regulate the proliferation of intestinal mucosal cells via a barrier effect and inhibition of DNA damage. The composition of gut microbiota and the influences of diet, drugs, and gender on the composition of the intestinal flora are important factors in the early detection of CRC and prediction of the results of CRC treatment. Regulation of gut microbiota is one of the most promising new strategies for CRC treatment, and it is essential to clarify the effect of gut microbiota on CRC and its possible mechanisms to facilitate the prevention and treatment of CRC. This review discusses the role of gut microbiota in the pathogenesis of CRC, the potential of gut microbiota as biomarkers for CRC, and therapeutic approaches to CRC based on the regulation of gut microbiota. It might provide new ideas for the use of gut microbiota in the prevention and treatment of CRC in the near future and thus reduce the incidence of CRC.

6 citations

Journal ArticleDOI
TL;DR: GBEVs are lipid bilayer nanoparticles secreted by the gut microbiota and are considered key players in bacteria-bacteria and bacteria-host communication, and the potential clinical applications of GBEVs is reviewed.
Abstract: ABSTRACT Intestinal microenvironment dysbiosis is one of the major causes of diseases, such as obesity, diabetes, inflammatory bowel disease, and colon cancer. Microbiota-based strategies have excellent clinical potential in the treatment of repetitive and refractory diseases; however, the underlying regulatory mechanisms remain elusive. Identification of the internal regulatory mechanism of the gut microbiome and the interaction mechanisms involving bacteria-host is essential to achieve precise control of the gut microbiome and obtain effective clinical data. Gut bacteria-derived extracellular vesicles (GBEVs) are lipid bilayer nanoparticles secreted by the gut microbiota and are considered key players in bacteria-bacteria and bacteria-host communication. This review focusses on the role of GBEVs in gut microbiota interactions and bacteria-host communication, and the potential clinical applications of GBEVs.

5 citations